Your session is about to expire
← Back to Search
Pembrolizumab for Merkel Cell Carcinoma
Study Summary
This trial is testing a new cancer treatment called pembrolizumab in people with Merkel Cell Carcinoma who have not had treatment before. The goal is to see if it is effective and safe.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 3 trial • 55 Patients • NCT03783078Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I had radiotherapy less than 2 weeks before starting the study treatment.I have not received a live vaccine in the last 30 days.I have or had lung inflammation that needed steroids.I haven't had surgery or radiation for local cancer, but it's okay if my cancer is now advanced or can't be removed.I have a tumor that can be measured by CT or MRI.Side effects from my last treatment are mild or gone, except for hair loss.I am mostly active and can carry out daily tasks.I am not pregnant or breastfeeding, and if I can have children, I use effective birth control or practice abstinence.I haven't had serious heart problems like heart failure, unstable chest pain, heart attack, stroke, or dangerous irregular heartbeat in the last 6 months.I have had cancer treatment or been in a trial within the last 12 weeks.I have received a transplant from another person.I am at least 12 years old and can consent to treatment.My organs are working well.I have brain metastases or cancer in the lining of my brain, with some exceptions.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I am currently being treated for an infection.I have an active tuberculosis infection.I have another cancer besides the one being studied, but it hasn't needed treatment in the last 2 years.My Merkel cell carcinoma has returned after surgery or radiation, or it has spread widely.I have an autoimmune disease treated with strong medication in the last 2 years.You have been diagnosed with HIV.You have had a severe allergic reaction to pembrolizumab or any of its ingredients.I haven't been treated for advanced cancer, but I may have had certain previous treatments.You have a history of Hepatitis B or active Hepatitis C infection.I have been treated with specific immune therapy for cancer.
- Group 1: Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the Pembrolizumab (MK-3475) patient safety profile like?
"Pembrolizumab (MK-3475) has received a 3 for safety. This is due to the fact that it is a Phase 3 trial, meaning there is both efficacy and safety data supporting its use."
Are we still looking for participants in this experiment?
"At the moment, this study is not enrolling patients. According to the information available on clinicaltrials.gov, it was first posted on February 25th, 2019 and last updated on July 8th, 2022. However, there are presently 2555 other clinical trials actively recruiting patients with carcinoma and 1000 studies for Pembrolizumab (MK-3475) that need participants."
Are there other investigations that have been done using Pembrolizumab (MK-3475)?
"Pembrolizumab (MK-3475) is being studied in 1000 live clinical trials, with 122 of those studies in Phase 3. The majority of Pembrolizumab (MK-3475) trials are based out of Houston, Texas; however, there are 36021 locations running Pembrolizumab (MK-3475) trials globally."
What are Pembrolizumab's (MK-3475) therapeutic indications?
"Pembrolizumab (MK-3475) is the standard care for patients with malignant neoplasms. Additionally, this immunotherapy drug has shown efficacy in treating other conditions like unresectable melanoma, microsatellite instability high, and disease progression after chemotherapy."
How many people meet the requirements to participate in this trial?
"This study is no longer recruiting patients for participation. The original posting date was February 25th, 2019 and the most recent update was on July 8th, 2022. However, there are still over 2500 active clinical trials searching for participants with carcinoma and 1000 studies related to Pembrolizumab (MK-3475)."
Share this study with friends
Copy Link
Messenger